Draig Therapeutics Ltd, a clinical-stage company in neuropsychiatric disorders, has appointed Ivana Magovčević-Liebisch as president and chief executive officer. She succeeds Ruth McKernan who continues as a director on the company’s board. The executive brings more than 25 years of biopharmaceutical leadership and experience, most recently as president and CEO of Vigil Neuroscience, a company she founded, built and led until its acquisition by Sanofi SA in August 2025.
Earlier roles included chief business officer at Ipsen and head of global business development for the specialty drug business at Teva Pharmaceutical Industries. Draig was launched in the UK in June following $140 million in Series A financing. It is starting a Phase 2 trial of DT-101, a differentiated AMPAR positive allosteric modulator, for the treatment of major depressive disorder.
Draig Therapeutics announced the appointment on 3 November 2025.
Copyright 2025 Evernow Publishing Ltd.